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 Vps34 controls intracellular trafficking, migration and platelet production in 
megakaryocytes. 


























To uncover the role of Vps34, the sole class III phosphoinositide 3-kinase, in megakaryocytes 
(MKs) and platelets, we created a mouse model with Vps34 deletion in the MK/platelet 
lineage (Pf4-Cre/Vps34
lox/lox
). Deletion of Vps34 in MKs led to the loss of its regulator 
protein Vps15, and was associated with microthrombocytopenia and platelet granule 
abnormalities. While Vps34 deficiency did not impact on MK polyploidisation or proplatelet 
formation, it dampened MK granule biogenesis and directional migration towards an SDF1 
gradient, leading to ectopic platelet release within the bone marrow. In MKs, the level of 
phosphatidylinositol 3-monophosphate (PI3P) was significantly reduced by Vps34 deletion 
resulting in endocytic/trafficking defects. In platelets, the basal level of PI3P was only slightly 
affected by Vps34 loss while the stimulation-dependent pool of PI3P was significantly 
decreased. Accordingly, a significant increase in the specific activity of Vps34 lipid kinase 
was observed following acute platelet stimulation. Similar as in Vps34-deficient platelets, ex 
vivo treatment of WT mouse or human platelets with Vps34 specific inhibitors, SAR405 and 
VPS34-IN1, induced abnormal secretion and affected thrombus growth at arterial shear rate, 
indicating a role for Vps34 kinase activity in platelet activation, independently from its role in 
MKs. In vivo, Vps34 deficiency had no impact on tail bleeding time but significantly reduced 
platelet prothrombotic capacity following carotid injury. This study uncovers a dual role for 
Vps34 as a regulator of platelet production by MKs and as an unexpected regulator of platelet 




Phosphoinositide 3-kinases (PI3Ks) are important lipid kinases producing D3-phosphorylated 
phosphoinositides that organize functional protein complexes regulating various biological 
processes
1,2
. The sole class III PI3K, Vps34, represents the most ancient form of PI3Ks and 
was initially identified in yeast with an essential role in vacuolar homeostasis
3
. Vps34 occurs 
in complex with its regulatory protein kinase subunit, Vps15 and specifically catalyzes the 
conversion of phosphatidylinositol into phosphatidylinositol 3-monophosphate (PI3P). This 
lipid, present in relatively low amounts in cells, is known to play a central role in the 
regulation of intracellular trafficking
4
. In mammals, Vps34 has been shown to regulate 
endosomal trafficking, autophagosome formation and mTOR activation through PI3P 
production
5
. Recently, the organismal role of Vps34 has been investigated using mouse gene 
targeting strategies. Loss of the Pik3c3 gene in mouse causes early embryonic lethality 
(between E7.5 and E8.5) due to severe decreased cell proliferation capacity
6
. In vivo studies 









 and skeletal muscle
12
 functions and in sensory, cortical and 
hippocampal neuron integrity
13,14
 by regulating, through two different protein complexes, 
endosomal and/or the autophagic pathways.  
At present, the role of Vps34 and its lipid product, PI3P, remains unknown in megakaryocytes 
(MKs) and platelets. Platelets are small anucleated blood cells playing a pivotal role in 
preventing excessive blood loss in response to vascular injury by adhering to exposed 
extracellular matrix and forming an haemostatic plug. Platelets are also strongly involved in 
atherothrombosis, a major cause of death worldwide, and are the target of anti-thrombotic 
drugs. To daily produce around 10
11
 platelets into the circulation, MKs migrate close to bone 
marrow sinusoids and protrude long cytoplasmic extensions called proplatelets into the 
sinusoidal lumen to release de novo circulating platelets
15
. In MKs and platelets, endocytosis 
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The aim of this study was to define the role for the Vps34/PI3P axis in MK differentiation and 
platelet production and function. This is important to provide new insights into these complex 
mechanisms and also, because Vps34 inhibitors which may impact on haemostasis are under 
development to improve chemotherapy
20,21
. To tackle these questions we used both a genetic 
approach in mice and pharmacological inhibitors. We show that Vps34 has two important 
roles: i) for platelet production in MKs where it controls the production of an important pool 
of PI3P, regulates MK migration and the subsequent platelet release in the blood, and impacts 
on trafficking and granule biogenesis, and ii) for platelet functions where it controls the 
production of a stimulation-dependent pool of PI3P that modulates platelet secretion and 
thrombus growth under arterial shear stress. This study provides new insights into the 
importance of the Vps34/PI3P axis as a regulator of both platelet production by MKs and 




Animals: 8 to 14 weeks-old C57BL/6 mice were used for all experiments and housed in the 
Anexplo (Toulouse) vivarium according to institutional guidelines. Ethical approval for animal 
experiments was obtained from the French Ministry of Research in agreement with European 
Union guidelines. 
Human blood samples: Heparinized blood from healthy donors was purchased from the 
Etablissement Français du Sang (Toulouse) and immediately processed for experiments.  
In vitro PI3K activity assay and lipid analysis: Vps34 immunoprecipitation and in vitro 
kinase assay were performed on washed platelets as previously described
22
. PI3P mass assay 
and phosphoinositide labeling were performed as previously described
23,24
.  
Primary MK purification and culture, immunofluorescence and flow cytometry on 
mature MKs as well as electron microscopy on native bone marrow and proplatelet 
formation assay from bone marrow explants are described in the supplemental Methods.   
MK migration assay: Chemotaxis was assessed using a Dunn chamber (Chemotaxis Dunn, 
Hawksley). MKs were allowed to adhere onto fibronectin-coated coverslips (20 μg/mL) at 
37°C for 1 h. The coverslip was then placed onto the Dunn chamber where the inner well was 
filled with serum-free medium and the outer well with serum-free medium containing 300 
ng/mL of SDF1α. Videomicroscopy was performed for 6 h with an Axio Observer.Z1 
inverted microscope operated with Zen software (Carl Zeiss) using an ORCA R2 camera 
(Hamamatsu, Japan) and a 10x, 0.30 EC Plan Neofluar objective lens. Migration analysis was 
performed using ImageJ and Chemotaxis tool plug-in.  
Bone marrow immunostaining: Mouse femora were fixed with 4% paraformaldehyde and 
5 mM sucrose and dehydrated using a graded sucrose series. Subsequently, the samples were 
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embedded in OCT matrix (CellPath) and shock-frozen in liquid nitrogen. Five-micrometre-
thick cryosections were probed with rabbit anti-human vWF antibody to specifically label 
MKs/platelets and mouse/rat anti-mouse FABP4/A-FABP antibody to stain microvascular 
endothelial cells
25
 followed by Alexa Fluor® secondary antibodies. Nuclei were stained using 
DAPI. Samples were visualized with a LSM780 operated with Zen software (Carl Zeiss) 
using a 63x, 1.4 NA Plan Apochromatic objective lens (Carl Zeiss). Image analysis was 
performed using ImageJ. 
Platelet lifespan, immune-induced thrombocytopenia, carotid artery thrombosis and tail 
bleeding time are described in the supplemental Methods.   
Washed murine platelet preparation, flow cytometry, electron microscopy, aggregation, 
secretion, αIIbβ3 integrin function assays and thrombus formation assays on collagen 
are described in the supplemental Methods.   
Statistical analysis: Data are expressed as mean ± SEM. Significance of differences was 
determined using two-tailed Student’s test, one-way ANOVA, two-way ANOVA or one 




Conditional genetic invalidation of Vps34 in the MK/platelet lineage 
To generate a mouse model with conditional invalidation of Vps34 activity, exon 21 of the 
kinase domain of the Pik3c3 gene was flanked with LoxP sites (Pik3c3
lox
, B.B. and B.V., 
manuscript in preparation). Excision of exon 21 encoding the kinase domain of Vps34 
specifically in the MK/platelet lineage was obtained by breeding Pik3c3
lox/lox
 mice with Pf4-
Cre transgenic mice to generate Pf4-Cre-Pik3c3
lox/lox
 mice (referred to as Vps34 in the 
figures). Littermate Pik3c3
lox/lox
 (referred to as WT) mice were used as controls. Platelet and 
MK lysates were analyzed by western blotting to assess the stability of the Vps34 protein 
lacking the exon 21 coding sequence. A dramatic reduction in Vps34 protein expression level 
was observed specifically in MKs (84.3% ± 2.6%) and platelets (87.8% ± 1.5%) from Pf4-
Cre-Pik3c3
lox/lox
 mice (Figure S1A and S1B). Similarly, the level of Vps15, a Vps34 
regulatory and associated protein kinase, was also strongly decreased in MKs and platelets 
from Pf4-Cre-Pik3c3
lox/lox
 mice (Figure S1A). This correlates with a previous study reporting 
the requirement of Vps34 to maintain the protein complex integrity
26
. Vps34 deletion had no 
impact on class I and II PI3K isoform expression in MKs and platelets (Figure S1A). Some 
residual lipid kinase activity (17.1% ± 4.1%) was detected in Vps34 immunoprecipitates from 
Vps34-deficient platelets (Figure S1C) suggesting efficient but incomplete Cre recombinase 
activity. Pf4-Cre-Pik3c3
lox/lox
 mice are viable and fertile, develop normally with no apparent 
morphological abnormalities and showed no signs of spontaneous bleeding. 
 
Mild microthrombopenia and platelet granule abnormalities in the absence of Vps34  
Deletion of Vps34 in the MK/platelet lineage resulted in a microthrombocytopenia of 
moderated intensity. As shown in Figure 1A, there was a significant reduction in the platelet 





 mice versus 7.39 μm3 ± 0.22 μm3 for WT mice, p<0.01; with a 
significant increase in mice with a mean platelet volume between 4 and 7 µm
3
). Expression 
levels of major platelet surface receptors (21, IIb3, GPVI and functional GPIb-IX-V) 
were comparable in Pf4-Cre-Pik3c3
lox/lox
 and WT platelets (Figure S1D and Videos 1 and 2).  
Circulating platelet count and size are the net result of a balance between platelet production 
and clearance that can be evaluated by in vivo measurements of platelet count recovery after 
immune-induced depletion and platelet lifespan. As shown in Figure 1B and C, platelet 
lifespan was normal in Pf4-Cre-Pik3c3
lox/lox
 mice whereas platelet production was altered. 
Despite a normal platelet recovery kinetic following anti-GPIbα antibody-induced 
thrombocytopenia, a reduced number of platelets was produced in Pf4-Cre-Pik3c3
lox/lox
 mice 
(Figure 1C). Accordingly, serum TPO levels, which are classically inversely proportional to 
platelet count, were significantly elevated in Pf4-Cre-Pik3c3
lox/lox
 (Figure 1C). However, 
increased TPO levels can also reflect abnormalities in clathrin-dependent endocytosis of its 
receptor, Mpl
19,27
. While total and surface expression of Mpl in resting WT and Vps34-
deficient platelets were comparable (Figure S2A), we observed a significant decrease in Mpl 
endocytosis after 20 minutes of TPO stimulation in Vps34-deficient platelets (Figure 1C). 
This indicates that elevated serum TPO levels results from a decreased platelet count and a 
defective Mpl endocytosis in platelets from Pf4-Cre-Pik3c3
lox/lox
 mice. Overall, these findings 
show that Pf4-Cre-Pik3c3
lox/lox
 mice microthrombocytopenia is due to a defective platelet 
production by MKs. 
Morphological analysis by transmission electron microscopy (TEM) revealed an abnormal 
granule distribution in Vps34-deficient platelets (Figure 1D). These platelets displayed a 
33.2% ± 3.1% reduction in the number and a 44.5% ± 3.4% increase in the size of α-granules 
compared to WT (Figure 1D). Abnormalities of dense granules were also observed with a 
44.8% ± 3.1% reduction in number compared to WT (Figure 1D). We also found that 
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fibrinogen internalization was significantly delayed in Vps34-deficient platelets (Figure S2B). 
Thus, the decreased efficiency of IIb3/fibrinogen and Mpl/TPO endocytosis demonstrate 
an important contribution of Vps34 in clathrin-mediated endocytosis in platelets. Despite a 
delayed endocytosis in Vps34-deficient platelets, α- or dense- granule contents (von 
Willebrand factor (vWF), fibrinogen or serotonin) in Vps34-deficient platelets were similar to 
that of WT platelets (Figure S2C). Of note, platelet mitochondrial content and activity 
appeared normal in Vps34-deficient platelets (Figure S2D).  
Overall, these data indicate that Vps34 specifically regulates platelet production, endocytosis 
and granule homeostasis. 
 
Vps34 is critical for MK migration and granule biogenesis 
To gain insight into the mechanisms leading to the observed platelet phenotype, we then 
analyzed MK morphology and functions. As shown in Figure 2A and Figure S3A-C, resident 
bone marrow MKs or bone marrow-derived MKs from Pf4-Cre-Pik3c3
lox/lox
 mice displayed 
similar number, size, ploidy levels, demarcation membrane system and proplatelet-producing 
capacity compared to WT MKs. MK ploidy levels and proplatelet extension were also not 
affected following pharmacological inhibition of Vps34 using the specific Vps34 inhibitor, 
VPS34-IN1
20
 (Figure S3B and S3C). However, transmission electron microscopy of MKs in 
their native bone marrow showed that Vps34-deficient MKs display less (21.4% ± 3.7% 
reduction in number) but bigger (26.5% ± 2.4% increase in size) -granules compared to WT 
MKs (Figure 2A), indicating that platelet granule defects originate from an abnormal 
biogenesis in MKs.  
An important stage of megakaryopoiesis prior to platelet release in the circulation is MK 
migration from the proliferative osteoblastic niche to the capillary-rich vascular niche in 
response to an SDF1α gradient28. We found that in vitro MK migration toward an SDF1α 
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gradient on fibronectin, a major extracellular matrix component of the bone marrow
29
, was 
significantly affected when Vps34 is absent or inhibited. While the migration distance was 
comparable to WT MKs, deficiency or inhibition of Vps34 induced a significant reduction in 
megakaryocyte directionality towards SDF1α. The migration paths demonstrated that Vps34-
deficient MKs moved over short distances before changing direction indicating a lack of 
directional persistence towards the SDF1gradient (Figure 2B). Immunostaining of bone 
marrow sections of intact femora showed that Vps34-deficient MKs more frequently released 
platelets outside the sinusoids directly into the bone marrow compartment than WT MKs 
(Figure 2C). Altogether, these findings are consistent with a critical role for Vps34 in 
regulating directional MK migration and the subsequent platelet release into sinusoid vessels. 
This strongly suggests that thrombocytopenia in Pf4-Cre-Pik3c3
lox/lox
 mice is caused by the 
inability of mature MKs to reach bone marrow sinusoids resulting in the observed ectopic 
platelet release.  
 
Vps34 deletion impacts on intracellular trafficking and PI3P production in MKs 
Both cell migration
30
 and granule biogenesis
17,18
 are regulated by intracellular trafficking 
mechanisms such as endocytosis, recycling and/or degradation. Besides normal transferrin 
receptor and IIb3 integrin surface expression levels (Figure S3D), Vps34-deficient MKs 
displayed a significant reduction in transferrin and fibrinogen endocytosis after 20 min 
(Figure 3A and 3B). Moreover, large and less abundant fibrinogen-containing vesicles were 
observed over time by super resolution microscopy in Vps34-deficient MKs compared to WT 
MKs (Figure 3C). These data show the important role of Vps34 in clathrin mediated-
endocytosis in MKs as observed for platelets (Figure 1C and S2B) and highlight its role in 
trafficking from the plasma membrane to granules in MKs. Consistent with these trafficking 
defects, we found by confocal microscopy a significant decreased number and increased size 
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of clathrin-positive vesicles as well as an accumulation of large early endosomes, as shown by 
an increased number (28.2% ± 2.7%) and size (16.7% ± 2.5%) of EEA1-positive vesicles in 
Vps34-deficient MKs (Figure 3D). Confocal analysis of LAMP1 and lysotracker labelling 
demonstrated a defect in early endosome to lysosome transition in Vps34-deficient MKs 
compared to WT MKs. In addition, Rab11 labeling demonstrated a decrease in the number 
(43.9% ± 4.4%) and size (22.5% ± 1.3%) of recycling endosomes in Vps34-deficient MKs 
(Figure 3E). This is consistent with elevated level of internalized transferrin at late time points 
(60 and 120 min) (Figure 3A) and point to an impaired endosomal recycling. Altogether, 
these data show the existence of a general trafficking defect in Vps34-deficient MKs. This 
defect was not due to a loss of clathrin, early endosomal Rab5, late endosomal Rab7 or 
recycling endosomal Rab 11 GTPases expression (Figure S3E). Interestingly, the level of 
Vps34 lipid product, PI3P, quantified by a specific mass assay
23
 and confocal microscopy 
using a specific anti-PI3P antibody, showed a significant reduction in Vps34-deficient MKs 
(Figure 3F and G). This reduction (from 30 to 40% compared to WT MKs) demonstrates the 
significant contribution of Vps34 to the level of PI3P but also suggested the existence of other 
enzymatic sources of PI3P in MKs. Overall, these data indicate a role for Vps34 in PI3P 
production and in the regulation of the endocytic/endosomal pathway in MKs with 
consequences in fibrinogen trafficking and in turn granule biogenesis.  
 
In platelets, Vps34 is critical for the stimulation-dependent PI3P pool, but not for the 
basal PI3P pool 
We next analyzed the impact of Vps34 deletion or inhibition in platelets using our mouse 
model and the Vps34 specific inhibitors (VPS34-IN1 and SAR405)
20,21
. We first focused on 
the production of PI3P by using both a specific mass assay
23
 quantifying the total PI3P 
amount and an HPLC analysis
24
 following short term 
32
Pi-labelling to determine the acute 
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changes in phosphoinositides following platelet stimulation. In resting platelets, the level of 
PI3P was modestly decreased (10.1% ± 1.3%) when Vps34 was deficient or 
pharmacologically inhibited with VPS34-IN1 (Figure 4A). Surprisingly, following CRP or 
thrombin stimulation, the inducible pool of PI3P was clearly affected (Figure 4B). HPLC 
analysis confirmed these defective responses (Figure 4C). No significant difference was 
observed in the amount of other lipid messengers including phosphatidylinositol 3,4-
bisphosphate (PI(3,4)P2), phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) and 
phosphatidic acid in resting or agonist-stimulated platelets (Figure S4). These data indicate 
that Vps34 is responsible for a small pool of basal PI3P in platelets and strongly involved in 
the agonist-dependent-pool of PI3P. To check whether Vps34 could be activated during 
platelet stimulation, we assayed its lipid kinase activity after immunoprecipitation. Acute WT 
platelet stimulations with thrombin or CRP resulted in a significant increase in Vps34 lipid 
kinase specific activity (Figure 4D). These data implicate a role for Vps34 activity in acute 
platelet stimulation.   
 
Vps34 kinase activity regulates thrombus growth  
We first tested the implication of Vps34 in platelet responses in vivo and found a normal tail 
bleeding time of Pf4-Cre-Pik3c3
lox/lox
 mice (Figure 5A). The prothrombotic function of 
platelets tested after FeCl3-induced mouse carotid injury was significantly decreased with 
nearly 50% of Pf4-Cre-Pik3c3
lox/lox
 mice protected against occlusive arterial thrombus 
formation (Figure 5B).  
Ex vivo thrombus formation assay performed under physiological arterial or arteriolar wall 
shear rates (500 and 1500 s
-1
 respectively) using Pf4-Cre-Pik3c3
lox/lox 
mice blood perfused 
over a collagen surface showed that Vps34-deficient platelets, despite their ability to normally 
attach to collagen fibres (Figure S5A), formed significantly smaller thrombi compared to WT 
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platelets (Figure 5C and D). When WT mice blood was treated ex vivo with Vps34 inhibitors 
and then perfused on a collagen matrix, thrombus formation was affected to a similar extent 
as for Pf4-Cre-Pik3c3
lox/lox 
mice blood (Figure S5B). Importantly, when human blood was 
treated with Vps34 inhibitors, again a similar defect in thrombus growth was observed (Figure 
5E). These data demonstrate that inhibition of Vps34 kinase activity in platelets, 
independently of its implication in MKs and platelet production, decreases platelet thrombus 
growth at arterial and arteriolar flow.  
 
Vps34 kinase activity is required for controlled platelet secretion 
To further analyze the thrombus formation defect, we performed aggregometry assays on 
platelets from Pf4-Cre-Pik3c3
lox/lox 
mice and on human platelets treated with the Vps34 
inhibitor. The mouse platelet aggregation responses to CRP, collagen, thrombin, thromboxane 
A2 analogue or ADP were not affected by Vps34 deficiency (Figure S6A). Platelet shape 
change and filopodia formation were also normal (Figure S6B) as well as thrombin or CRP-
induced JON/A binding, reflecting normal αIIbβ3 integrin activation (Figure S6C). PI3P is 
known to contribute to the regulation of NADPH oxidase complex subunits
31
, therefore we 
measured the production of reactive oxygen species in response to CRP or thrombin. This 
production was not affected in Vps34-deficient platelets nor was the thromboxane A2 
production (Figure S6D and S6E), consistent with the fact that indomethacin treatment did not 
modify the thrombus growth difference between WT and Pf4-Cre-Pik3c3
lox/lox 
mice blood 
(Figure S6F). Aggregation responses of human platelets were also not affected following 
pharmacological inhibition of Vps34 (Figure S6G).  
Interestingly, in the absence of Vps34 and despite a normal amount of granule content (Figure 
S2C), dense granule release (assessed by ATP secretion; Figure 6A) as well as α-granule 
release (assessed by vWF secretion; Figure 6B) were significantly faster and exacerbated in 
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response to platelet acute stimulation. This increased secretion response was also observed 
after treatment of WT platelets with the Vps34 inhibitor (Figure 6C and D). Consistent with 
this, Vps34-deficient platelets displayed an enhanced spreading on fibrinogen that was fully 
counteracted by hydrolysis of secreted ATP/ADP by addition of apyrase (Figure 6E). Since a 
low solute transport is important to maintain elevated concentration of molecules secreted by 
platelets within the thrombus and to allow efficient thrombus growth
32,33
, we checked whether 
the exacerbated secretion response could influence thrombus formation under arterial flow 
condition. Measurement of the serotonin level, in Pf4-Cre-Pik3c3
lox/lox 
mice whole blood or 
WT mice whole blood treated with Vps34 inhibitor, recovered after perfusion on a collagen 
matrix showed an increased level of serotonin. This indicates that Vps34-deficient platelets or 
Vps34-inhibited WT platelets forming thrombi on collagen surface had an exacerbated 
secretion, resulting in higher level of secreted molecules in the circulation (Figure 6F). 
Accordingly, when DiOC6-labelled whole blood from WT mice was perfused under 
physiological shear rate over preformed WT or Pf4-Cre-Pik3c3
lox/lox
 thrombi, we observed 
that Vps34-deficient platelet thrombi were significantly less efficient to recruit WT circulating 
platelets to allow thrombus growth (Figure 6G).  
Taken together, these data show that Vps34 kinase activity controls the intensity and timing of 
platelet secretion, which likely impacts on thrombus growth under arterial wall shear rate. 
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DISCUSSION   
By creating a mouse model of MK/platelet lineage-specific Vps34 deletion and using two 
unrelated Vps34 selective inhibitors, we revealed a dual role for Vps34 in MKs and in 
platelets. Pf4-Cre-Pik3c3
lox/lox
 mice displayed a moderate microthrombocytopenia due to a 
platelet production defect rather than an abnormal platelet lifespan. While nuclear and 
membrane maturation as well as proplatelet extension were normal in MKs when Vps34 is 
absent or inhibited, directional MK migration towards a SDF1 gradient was strongly 
affected. In the bone marrow, MKs migrate from the osteoblastic niche to the vascular niche 
to deliver platelets in the blood flow. Most likely as a result of this directional migration 
defect, Pf4-Cre-Pik3c3
lox/lox
 mice showed an increased presence of platelets in the bone 
marrow outside the sinusoidal vessels, consistent with the mild microthrombocytopenia 
observed in these mice. Of note, this is also the case of patients with Wiskott-Aldrich 
syndrome (WAS) and profilin 1-deficient mice where microthrombocytopenia has been 
reported to result from accelerated platelet turn-over and premature platelet release into the 
bone marrow associated to defective MK migration towards the SDF1 gradient34,35. Directed 
cell migration is a spatially organized process, governed by the cell ability to sense chemokine 
gradient and then transduce adequate signalling for the cell to polarize and move by 
chemotaxis that depends on intracellular trafficking of cell surface receptors
30
. 
SDF1receptor-driven CXCR4 polarization has been shown to be important for MK directed 
migration towards an SDF1 gradient36. Thus, a defect that might explain the lack of 
directional migration of Vps34-deficient MKs is the herein documented defective trafficking 
(clathrin-mediated endocytosis and recycling) and the subsequent inadequate positioning of 
the SDF1receptor, CXCR4, at the migration front. Unfortunately, the lack of efficient 
molecular tools to study CXCR4 in primary MKs did not allow us to evaluate this hypothesis. 
Impaired trafficking of other receptors, such as the fibronectin receptor 51 integrin since 
17 
 
migration was assayed on a fibronectin matrix, could take part into the lack of MK 
directionality and in turn cause ectopic platelet release within the bone marrow
37
. This study 
implements the short list of publications highlighting the important role of endocytosis in 
MKs and platelets
16,19
. For instance, deletion of dynamin 2, a major actor of clathrin-mediated 
endocytosis, in MKs and platelets has been shown to strongly affect Mpl endocytosis 
associated to MK hyperplasia and myelofibrosis
19
. Deletion of Vps34 in platelets also impacts 
Mpl and fibrinogen endocytosis but with a somehow different associated phenotype (i.e. 
moderated microthrombocytopenia without MK hyperplasia) probably due to a different 
degree of implication of the two proteins in endocytosis and to their impact in other cellular 
processes. 
The α- and dense- granules originate from a multivesicular bodies (MVBs)/late endosome 
compartment where cargos derive from both a secretory pathway from the golgi network and 
an endocytic pathway from plasma membrane through highly regulated and still poorly 
known sorting processes
17,18
. Thus, the aberrant granule biogenesis, highlighted by the 
disturbed fibrinogen uptake, is consistent with a general trafficking defect of Vps34-deficient 
MKs and platelets.  
PI3P is an important lipid in the regulation of the endocytic pathway and Vps34 has been 
proposed as the major PI3P producing kinase in mammalian cells
4,5
. Our results show that in 
MKs, Vps34 controls approximately 40% of the PI3P level, indicating the contribution of 
other PI3K isoforms in the production of this lipid. Overall our results show that Vps34 
controls a PI3P pool important for the regulation of the endocytic and trafficking pathway in 
MKs. Although we observed a role for Vps34 and PI3P in autophagy in MKs (SS, CV 
unpublished observation), the trafficking defect shown here appears to be crucial in MK 
migration and granule biogenesis. This is consistent with the fact that Pf4-Cre-Atg7
lox/lox
 mice, 





Interestingly, in platelets, the contribution of Vps34 to the production of the basal pool of 
PI3P is very limited (~10%) when compared with the significant contribution of PI3KC2 
that we recently described
39
. Several routes of PI3P production probably account for 
maintaining basal levels of this important lipid, including Vps34 and mainly PI3KC2but 
also possibly 4- and/or 5-phosphatses acting on PI(3,4)P2 and/orPI(3,5)P2
40
. However, a 
significant fraction of the stimulation-dependent PI3P production requires Vps34 activity as 
shown in platelets from Pf4-Cre-Pik3c3
lox/lox
 mice and in WT platelets treated in vitro with 
Vps34 inhibitors. Accordingly, an increase in Vps34 kinase activity was observed following 
stimulation of WT platelets with G-protein coupled receptors or ITAM-linked receptors. 
Stimulation-dependent activation of Vps34 has also been suggested in insulin-stimulated 
hepatocytes
41
, pointing towards a role for Vps34 during acute cellular responses.  
Acute platelet activation can be triggered in vivo in a thrombosis model of carotid ferric 
chloride injury. Interestingly, loss of Vps34 in platelets had a significant protective role 
against occlusive arterial thrombus formation. The decrease in thrombus growth at arterial 
shear rate was confirmed in ex vivo thrombosis assays using Pf4-Cre-Pik3c3
lox/lox
 mice blood 
perfused over a collagen surface and was reproduced by treatment of blood from WT mice or 
human donors with Vps34 inhibitors, highlighting the important role of Vps34 kinase activity 
in this process and showing that this effect is not a consequence of Vps34 functions in MKs. 
Integrin αIIbβ3 activation and granule secretion are essential for the regulation of thrombus 
growth
42,43
. The activation of IIb3 integrin appeared not significantly altered in Vps34-
deficient platelets and Vps34-deficient washed platelet aggregation in suspension was normal. 
However, Vps34-deficient platelets showed an increased rate of secretion in response to 
several agonists in vitro and, importantly, ex vivo under arterial flow. Platelet secretion plays 
an important physiological role by discharging a variety of molecules contributing to platelet 
recruitment for adequate thrombus growth and organization. Mathematical models and in vivo 
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experiments have shown that the architecture of the thrombus (i.e. a stable core of fully-
activated, densely-packed platelets with an outer shell of less-activated loosely packed 
platelets) is the result of overlapping agonist gradients within the platelet mass
33,44,45
. 
Moreover, a stratified granule secretion has recently been observed in the thrombus with fully 
degranulated platelets at the base of the thrombus and granule-containing platelets at the 
vessel lumen
46
, demonstrating the importance of secretion events in thrombus formation and 
organisation. These data indicate that a fine-tuned spatial and temporal regulation of granule 
release, which is lost in the absence of platelet Vps34 activity, is crucial for normal platelet 
thrombus formation. Consistent with this, under arterial flow we showed that Vps34-deficient 
platelets displayed an exacerbated secretion and were less efficient to recruit circulating WT 
platelets to the growing thrombus. It is not clear at present how Vps34 and its product PI3P 
contribute to the spatio-temporal platelet secretion but it is most likely due to the recruitment 
of intracellular proteins that regulate granule fusion and/or secretion.  
In conclusion, our study points to a dual function for Vps34 in MKs and platelets. In MKs, 
Vps34 controls the production of an important pool of PI3P and regulates clathrin-dependent 
endocytosis and trafficking which in turn impacts on MK migration and the subsequent 
platelet release in the blood as well as granule biogenesis. In platelets, Vps34 mainly controls 
the production of a stimulus-dependent pool of PI3P and platelet secretion, thereby impacting 
on thrombus growth under arterial flow. This study provides new insights into the effects of 
Vps34 inhibitors in haemostasis and thrombosis that will have to be taken into account if they 
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Figure 1: Defective platelet production and granule distribution in Vps34-deficient 
platelets. (A) Left Panel, Whole blood platelet count was measured using HORIBA ABX 
Micros 60 analyzer (mean ± SEM; n=38 mice for WT and 49 for Pf4-Cre-Pik3c3
lox/lox
 mice 
(Vps34)); ***p<0.001 versus WT according to two-tailed Student’s t test). Middle Panel, 
Quantification of the percentage of mice with a mean platelet volume ranging from 4 to 7 µm
3
 
and from 7 to 10 µm
3
 (mean ± SEM; n=38 mice for WT and 49 for Pf4-Cre-Pik3c3
lox/lox
 mice 
(Vps34)). Right Panel, Transmission electron microscopy of resting platelets. Images are 
representative of 5 mice of each genotype. Scale bar: 2 µm. (B) Mice were injected 
intravenously with a dylight
488
-anti-GPIb Ig derivative antibody. The percentage of labelled 
platelets in blood samples was measured at various time points after injection. (C) Left graph, 
Thrombocytopenia in mice was induced by intraperitoneal injection of anti-GPIbα antibody. 
Platelet count was measured in blood samples collected 6 h after injection (time=0) and at 
various time points. Middle graph, Mice serum TPO level was quantified by immunoassay. 
Right graph, Platelets were incubated with 50 ng/mL of TPO at the indicated times and 
incubated after fixation with a rat antibody against the extracellular domain of Mpl and an 
anti-rat Alexa Fluor®
488 
antibody. Graph is expressed as percentage of MFI (Mean 
Fluorescence Intensity) resting (0) values after flow cytometry analysis (mean ± SEM; n=4-6 
mice of each genotype, *p<0.05 versus WT according to two-way ANOVA test).  (D) 
Transmission electron microscopy of resting platelets. Images are representative of 5 mice of 
each genotype. Scale bar: 1.5 µm. Arrows indicate  granules. Platelet - and dense ()- 
granule number and mean area were measured on transmission electron microscopy images 
using ImageJ (mean ± SEM; n=5 mice of each genotype; *p<0.05, ***p<0.001 versus WT 




Figure 2: Vps34 is critical for MK migration and granule biogenesis. (A) Transmission 
electron microscopy of MKs from native bone marrow sections. Images are representative of 
5 mice of each genotype. Scale bar: 5 µm (upper images) and 1 µm (lower images). -granule 
number and mean area were quantified on 70 µm² field of transmission electron microscopy 
images using ImageJ (mean ± SEM; n=5 mice of each genotype; **p<0.01, ***p<0.001 
versus WT according to two-tailed Student’s t test). (B) WT or Vps34-deficient (Vps34) MKs 
were exposed to a SDF1 gradient within the Dunn chamber. Migration paths over 6 h of 5 
representative MKs from 8 independent experiments in each graph were traced. The 
intersection of the x- and y-axis was taken to be the starting point of each cell path, whereas 
the source of the SDF1 was at the top. Accumulated distance and directionality from WT 
MKs in presence of DMSO (WT) or 1 M VPS34-IN1 or from Vps34-deficient (Vps34) MKs 
were analyzed using ImageJ manual tracking plug-in (mean ± SEM; n=30-50 MKs from 8 
independent experiments; **p<0.01 versus WT according to one-way ANOVA test). (C) 
Representative confocal images of immunostained native bone marrow. MKs and platelets are 
labelled by vWF staining (green). FABP4/A-FABP staining (red) labels sinusoid vessels. 
Nucleus staining was done by DAPI (blue). Scale bars: 50 μm. Graph represents the 
percentage of platelets inside and outside the sinusoids (mean ± SEM; n= 20 images from 4 
mice of each genotype, ***p<0.001 versus WT according to two-tailed Student’s t test).  
 
Figure 3: Defective intracellular trafficking and PI3P production in Vps34-deficient 
MKs. (A-C) MKs uptake of transferrin-Alexa Fluor®
546
 (A) or fibrinogen-Alexa Fluor®
488
 
(B-C) was observed by confocal (A) or SIM super resolution microscopy (B-C) at different 
incubation time points. A-B: Graphs represent fluorescence intensity quantified on a MK z-
stack by ImageJ or Imaris software. C: Representative three-dimensional surface rendering of 
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z-stacks acquired after 960 min of fibrinogen uptake are shown. Scale bar: 5 µm. Graphs 
represent fibrinogen-positive structure number and volume quantified over time on three-
dimensional images using Imaris software. Data are expressed as mean ± SEM; n=10-60 MKs 
from 3 mice of each genotype; *p<0.05, ***p<0.001 versus WT according to two-way 
ANOVA test. (D-E) Fixed MKs stained with anti-clathrin, anti-EEA1, anti-Rab11 or anti-
LAMP1 antibodies followed by corresponding secondary Alexa Fluor®
488 
antibodies were 
observed by confocal microscopy. Live MKs were stained with LysoTracker® Deep Red, 
fixed and observed by confocal microscopy. Representative images of a z-stack are shown. 
Scale bar: 5 µm. Graphs represent structure number and area analyzed on a z-stack with 
ImageJ (mean ± SEM; n=30-50 MKs from 3 mice of each genotype; *p<0.05, ***p<0.001 
versus WT according to two-tailed Student’s t test). (F) PI3P mass assay performed on MKs 
as described in methods (mean ± SEM; n=5; **p<0.01 versus WT according one sample t 
test). (G) MKs stained with anti-PI3P and secondary Alexa Fluor®
488 
antibodies were 
observed by confocal microscopy and fluorescence intensity was quantified using ImageJ 
(mean ± SEM; n=40 MKs from 3 mice of each genotype; ***p<0.001 versus WT according 
to two-tailed Student’s t test).  
 
Figure 4: Vps34 regulates the stimulation-dependent PI3P production in platelets. (A) 
PI3P content was analysed by mass assay in washed resting WT platelets treated for 1 h with 
DMSO (WT) or 1 M VPS34-IN1 and Vps34-deficient platelets (Vps34) (mean ± SEM; n=3-
5; **p<0.01 versus WT according to one sample t test). (B) PI3P content from WT platelets 
treated for 1 h with DMSO (WT) or 1 M VPS34-IN1 and from Vps34-deficient platelets 
(Vps34) in resting or stimulated (CRP, 10 µg/ml; thrombin, 0.5 UI/ml) conditions was 
assessed by mass assay (mean ± SEM; n=5; *p<0.05; **p<0.01 versus WT according to two-
way ANOVA test). (C) HPLC analysis of PI3P level of resting and stimulated (CRP, 10 
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µg/ml; thrombin, 0.5 IU/ml) 
32
Pi-labelled platelets (mean ± SD; n=2). (D) Vps34 was 
immunoprecipitated from resting or activated (CRP, 10 µg/ml; thrombin, 0.5 IU/ml) washed 
platelets and assayed for lipid kinase activity in vitro. Graph represents Vps34 activity (fold 
increase) normalized to the levels of immunoprecipitated kinase in each condition as assessed 
by immunoblot and densitometry analysis (mean ± SEM; n=5; ***p<0.001 versus resting 
according to one sample t test). 
 
Figure 5: Vps34 plays an important role in thrombosis via its kinase activity. (A) Tail 
bleeding time (n=30 mice of each genotype) was measured as described in methods. (B) 
Thrombotic response of mice to carotid injury after exposure to 7.5 % FeCl3 for 3 min 
assessed by a flow probe. Graph represents percentage of mice without occlusion 30 min after 
injury (n=15 mice of each genotype; p=0.0002 according to one sample t test). (C-D) DiOC6-
labelled platelets in mice whole blood were perfused through collagen-coated microcapillaries 
at a physiological arterial shear rate of 500 s
-1 
(C) or at arteriolar shear rate of 1500 s
-1
 (D). 
Scale bar: 20 µm. Surface covered by fluorescent platelets and thrombus volume were 
analyzed using ImageJ (mean ± SEM; n=8 mice of each genotype; *p<0.05; **p<0.01 versus 
WT according to two-tailed Student’s t test and one sample t test). (E) Healthy human donor 
whole blood was treated with 1 µM VPS34-IN1, 1 µM SAR405 or vehicle (DMSO) for 1 h. 
Then, DiOC6-labelled whole blood was perfused through collagen-coated microcapillaries at a 
physiological shear rate of 1500 s
-1
. Scale bar: 20 µm. Surface covered by fluorescent 
platelets and thrombus volume were analyzed using ImageJ (mean ± SEM; n=3-5 healthy 
donors depending on the inhibitor; *p<0.05; **p<0.01 versus vehicle according to two-way 




Figure 6: Vps34 kinase activity regulates platelet secretion. (A) Kinetics of ATP secretion 
of washed platelets under resting or stimulated conditions (CRP, 1 µg/ml; thrombin, 0.1 
IU/ml) were recorded by measuring the luminescence from the firefly luciferin-luciferase 
reaction by lumi-aggregometry using the Chrono-log aggregometer. Graphs represent percent 
of WT maximal secretion at 80 sec (mean ± SEM; n=6-15 mice of each genotype depending 
on the agonist; *p<0.05, **p<0.01 ***p<0.001 versus WT according to two-way ANOVA). 
(B) Kinetics of vWF secretion of washed platelets under resting or CRP (1 µg/ml) or 
thrombin (0.1 IU/ml) stimulated condition was analyzed by ELISA assay. Results are 
expressed as fold increase compared to resting WT platelets (mean ± SEM; n=6 mice of each 
genotype; *p<0.05 versus resting WT according to two-way ANOVA). Kinetics of ATP 
secretion (C) and vWF secretion (D) of washed platelets treated 1 h with vehicle (DMSO) or 
1 M VPS34-IN1 and stimulated with CRP (1 µg/ml) or thrombin (0.1 IU/ml) were analyzed 
as described above (mean ± SEM; n=6; *p<0.05 versus resting WT according to two-way 
ANOVA). (E) Washed platelets were spread on a fibrinogen-coated surface for 20 min in 
presence or not of apyrase (2 IU/ml) and platelet surface was measured using ImageJ (mean ± 
SEM; n=3 mice per genotype; **p<0.01 versus WT according to two-way ANOVA). (F) 
Whole blood from WT mice treated for 1 h with DMSO (WT) or 1 M VPS34-IN1 or from 
Pf4-Cre-Pik3c3
lox/lox
 mice was perfused through a collagen-coated microcapillary in presence 
of fluoxetine (25 µM) at a physiological shear rate of 1500 s
-1
. Serotonin content was 
quantified in plasma by immunoassay (mean ± SEM normalized by thrombus volume; n=3-5 
per condition; ***p<0.001 versus WT according to one-way ANOVA test). (G) Unlabelled 
whole blood from WT or Pf4-Cre-Pik3c3
lox/lox
 (Vps34) mice were perfused through collagen-
coated microcapillaries at 1500 s
-1
 during 1 min and were then replaced by DiOC6-labelled 
WT whole blood perfused at the same shear rate. Surface covered by fluorescent platelets was 
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analyzed using ImageJ (mean ± SEM; n=5 mice of each genotype; ***p<0.001 versus 
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Materials: Dylight-anti-GPIbIg derivative, anti-GPIb-FITC, anti-2-FITC, JON/A-PE, 
anti-IIb3-PE, anti-GPVI-FITC and anti-GPIbα (for platelet depletion) antibodies were from 
Emfret Analytics. Anti-p110, anti-p110 anti-hsp90, anti-clathrin and anti-Vps34 (for 
western blotting) antibodies were purchased from Cell Signaling Technology. Vps34-IN1 was 
purchased from Medkoo Biosciences, Inc.  Anti-Vps34 antibody for immunoprecipitation and 
anti-PI3P antibody were from Echelon Biosciences Inc. Anti-Vps15 antibody was from 
Bethyl Laboratories Inc. Anti-p85 antibody was from Merck Millipore. Anti-FABP4/A-FABP 
antibody and Mouse Thrombopoietin Immunoassay were from RnDSystems. Serotonin 
ELISA test and anti-Mpl antibody against the extracellular domain were from IBL 
International. Anti-Mpl antibody for western-blotting was from Novus Biologicals
TM
. Anti-
human von Willebrand factor, anti-human von Willebrand factor HRP and anti-human 












propidium iodide were obtained from Molecular 
Probes
TM
. Biochips with microcapillaries (Vena8Fluoro+) were obtained from Cellix. Biotin-
conjugated rat anti-mouse CD45R/B220, purified rat anti-mouse CD16/CD32, anti-1-FITC, 
anti-GPIIb-FITC, anti-EEA1, anti-LAMP1, anti-PI3KC2 and anti-PI3KC2antibodies were 
from BD Pharmingen. Anti-Rab5 and anti-Rab7 antibodies were a gift from F. Alpy (IGBMC, 
Illkirch, France). Anti-mouse Gr1 and biotin anti-mouse CD11b antibodies were from 
eBioscience. Anti-Rab11 antibody, sheep anti-rat IgG Dynabeads and StemPro medium were 
from Invitrogen
TM
. Lipids were from Avanti Polar Lipids (Coger, Paris, France). CRP was 
from Pr. R. Farndale laboratory (Cambridge, UK). Collagen Reagent HORM
®
 (equine) 
suspension was purchased from Takeda. DIOC6 and Alexa Fluor®
488 
anti-mouse / rabbit or rat 
secondary antibodies were from Life Technologies. Recombinant murine TPO, SCF and 
SDF1 were obtained from Peprotech. All other reagents were purchased from Sigma-
Aldrich. 
MK purification and culture: Bone marrow cells were obtained from mouse femora and 









, were depleted using immunomagnetic beads (sheep anti-rat IgG Dynabeads). 
The remaining population was cultured in 2.6% serum-supplemented StemPro medium with 
2 mM L-glutamine, penicillin (100 IU/mL)/streptomycin (100 µg/mL), 20 ng/mL murine 
stem cell factor (SCF) and 50 ng/mL murine thrombopoietin (TPO) at 37°C under 5% CO2 
for 3 days. Mature MKs were isolated using a 1.5%-3% bovine serum albumin (BSA) 
gradient under gravity for 45 min at room temperature.  
Washed murine platelets were prepared as previously described
1
. 
Gel electrophoresis and immunoblotting: MKs or washed platelets were lysed in Laemmli 
electrophoresis sample buffer containing
 
100 mM Tris-HCl (pH 6.8), 15% (v/v) glycerol, 25 
mM DTT
 
and 3% SDS, boiled for 5 min, separated on SDS-PAGE, transferred
 
onto a 
nitrocellulose membrane (Gelman Sciences) and analyzed using the relevant antibody. 
Scanning and Transmission electron microscopy were performed on washed platelets and 
freshly isolated bone marrow from tibiae as previously described
1
. 
ELISA assays: Serotonin content was measured using IBL Serotonin ELISA test (RE59121, 
IBL) according to the manufacturer instructions. Serum TPO quantification was performed 
using RnDSystems Mouse Thrombopoietin Immunoassay (MTP00, RnDSystems) according 




Flow cytometry: For surface glycoprotein expression, platelets in whole blood or MKs were 
stained with anti-2-FITC, anti-GPVI-FITC, dylight-488-anti-GPIbIg derivative, anti-
GPIb-FITC, anti-1-FITC, anti-GPIIb or anti-IIb3-PE antibodies for 30 min at room 
temperature. For Mpl surface expression, washed platelets before or after TPO internalization 
were fixed with 1.5% formaldehyde for 20 min and incubated with a specific antibody 
directed against the extra-cellular domain of Mpl followed by a secondary Alexa Fluor®488 for 
2 h. For mitochondria content, washed platelets were incubated with a specific mitochondria 




Red mitochondrial superoxide 
indicator) for 30 min at 37°C. For ROS content, washed platelets were incubated with 
Dichloro-dihydro-fluorescein diacetate (DCFH-DA) for 30 min at 37°C. MK polyploidy was 
analyzed after MK fixation with 0.5% formalin and subsequent DNA staining with propidium 
iodide. Samples were analyzed using an LSRFortessa
TM
 Cell analyser flow cytometer and 
Diva software (Becton Dickinson). 
Immunofluorescence: MKs were allowed to adhere on a fibronectin-coated surface (20 
µg/mL) for 3 h at 37°C. For clathrin, EEA1, Rab11 and LAMP1 staining, MKs were fixed 
and permeabilized in one step with 3.7% formaldehyde and 0.05% Triton X100 for 45 min. 
Samples were saturated in 3% fatty acid free BSA for 20 min and incubated with primary 
antibody and the relevant Alexa Fluor®
488
 secondary antibody for 2 h at room temperature. 
PI3P labeling using specific anti-PI3P antibody was performed as previously described
3
. For 
lysosome content analysis, MKs were stained with LysoTracker® Deep Red (100 nM) for 30 
min, washed and fixed with 3.7% formaldehyde for 30 min. For endocytosis assays, MKs 
were incubated for 20 min at 4°C with 20 µg/mL transferrin-Alexa Fluor®
546 





washed and incubated for different times at 37°C before being 
fixed with 3.7% formaldehyde for 30 min. Confocal images were captured with a LSM780 
operated with Zen software using a 63x, 1.4 NA Plan Apochromatic objective lens (Carl 
Zeiss). SIM (Structured Illumination Microscopy) super-resolution was performed with an 
ELYRA.PS1 operated with Zen software (Carl Zeiss), using a 63x, 1.4 NA Plan-Apochromat 
lens and three rotations of a 51-μm grid. Images were captured with a sCMOS camera 
(Hamamatsu). Image analysis was processed with ImageJ or Imaris software. 




Platelet lifespan: Circulating platelets were labelled in vivo by intravenous injection of 
Dylight
488
-anti-GPIb Ig derivative (0.1 µg/g body weight). 2 h after antibody injection and 
every 24 h for 5 days, the percentage of the Dylight
488
-positive platelet population in whole 
blood from tail bleeding was determined using an LSRFortessa
TM
 Cell analyser flow 
cytometer and Diva software (BD Biosciences). 
Immune-induced thrombocytopenia: Thrombocytopenia was induced by intraperitoneal 
injection of anti-mouse GPIbα antibody (2 μg/g body weight). Blood samples were collected 
by tail bleeding at different times and platelet counts were measured using HORIBA ABX 
Micros 60 analyser. 
Platelet aggregation and dense granule secretion: Aggregation and adenosine
 
triphosphate 
(ATP) secretion were measured simultaneously under continuous stirring at 1000 rpm at 37°C 
using
 
a Born lumi-aggregometer (Chrono-Log).  
αIIbβ3 integrin function assays: For integrin activation, washed platelets (1 × 106) were 
stimulated with agonists at 37°C for 15 min in presence of 1 mM Ca
2+
 and incubated 
subsequently with PE-conjugated JON/A antibody for 30 min at room temperature before 
being analyzed using an LSRFortessa
TM
 Cell analyser flow cytometer and Diva software 
(Becton Dickinson). For spreading experiments, washed platelets (1 × 10
7
) were allowed to 
adhere and spread on fibrinogen coated-surface (100 μg/ml) for 20 min at 37°C. Platelets 
were fixed with 1.5% formaldehyde for 30 min, permeabilised with 0.1% Triton X100 for 10 
min and labelled with phalloidin Alexa Fluor®
488
. For endocytosis assays, platelets were 
incubated for different time points at 37°C with 30 µg/ml fibrinogen-Alexa Fluor®
488 
before 
being fixed with 1.5% formaldehyde for 30 min. Confocal images were captured with a 
LSM780 operated with Zen software using a 63x, 1.4 NA Plan Apochromatic objective lens 
(Carl Zeiss).  Image analysis was performed using ImageJ.  
Flow assay on collagen, carotid artery thrombosis and tail bleeding time were performed 
as previously described
1,5
. For platelet incorporation assay into an existing thrombus, 
unlabelled whole blood was perfused through a collagen-coated microcapillary at 1500 s
-1
. 
After 1 min of flow, blood was replaced by DiOC6-labelled whole blood and perfused for 1 
min 30 at 1500 s
-1
. The surface covered (%) by fluorescent platelets was then analyzed using 
ImageJ.  
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Figure S1: Conditional genetic inactivation of Vps34 in the MK/platelet lineage. (A) Western blot 
analysis for Vps34, Vps15, p110a, p110b, p85, PI3KC2a and PI3KC2b in platelet and MK lysates (mean ± 
SEM; n=3-6; ***p<0.001 versus WT according one sample t test). Actin represents the loading control. (B) 
Representative western blot for Vps34 expression in heart, liver, spleen, kidney and lung lysates. Hsp90 
represents the loading control. (C) Vps34 was immunoprecipitated from resting washed platelets and assayed 
for lipid kinase activity in vitro (mean ± SEM; n=5; ***p<0.001 versus WT according to one sample t test). (D) 
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Figure S2: Normal Mpl expression, granule content and mitochondria in Vps34-deficient platelets. (A) 
Total and surface expression of Mpl were analyzed by western blot and flow cytometry respectively. Actin is 
used as loading control. MFI: mean intensity fluorescence (mean ± SEM; n=3-6 mice of each genotype). (B) 
Platelets were incubated with fibrinogen-Alexa Fluor®488 and its internalisation was observed by confocal 
microscopy at different incubation times. Graph represents fluorescence intensity per platelets quantified 
using ImageJ (mean ± SEM; n=100 platelets from 3 mice of each genotype; *p<0.05, **p<0.01 versus WT 
according to two-way ANOVA test). (C) Platelet vWF, fibrinogen and serotonin global content were quantified 
by immunoassay or western blot (mean ± SEM; n=6 mice of each genotype). (D) Transmission electron 
microscopy images of platelet mitochondria representative from 3 mice of each genotype. Scale bar: 200 nm. 
Mitochondria area was quantified using ImageJ (mean ± SEM; n=3 mice/genotype). Platelet mitochondrial 
content and activity were assessed by flow cytometry using MitoTracker® RedFM and MitoSOXTM Red 


















Figure S3: No role for Vps34 in MK 
nuclear maturation and in proplatelet 
formation. (A) MK number and area 
were quantified on hemalin eosin stained 
native bone marrow sections using NDP 
view software (mean ± SEM; n=6 mice 
of each genotype and 50 MKs per 
mouse). (B) After 3 days of in vitro 
maturation in presence or not of VPS34-
IN1 (1µM), WT MKs or Vps34-depleted 
(Vps34) MKs were stained with 
propidium iodide and ploidy degree was 
evaluated by flow cytometry (mean ± 
SEM; n=4 independent experiments). 
(C) After bone marrow dissection, native 
MKs from WT or Pf4-Cre-Pik3c3lox/lox 
mice were imaged for 15 h by 
videomicroscopy in presence or not of 
VPS34-IN1 (1 µM). Time to proplatelet 
formation and proplatelet area were 
quantified using Zen software (mean ± 
SEM; n=60 and 38 MKs from 3 mice of 
each genotype). (D) MK surface labeling 
with transferrin-Alexa Fluor®546 or anti-
GPIIb-FITC antibody were analyzed by 
flow cytometry (mean ± SEM; n=3). (E) 
Western blot analysis of clathrin, Rab 5, 
Rab 7 and Rab 11 in MK lysates (mean 










Figure S4: Normal basal and inducible PI(3,4)P2, PI(3,4,5)P3 and phosphatidic acid levels in platelets. 
HPLC analysis of PI(3,4)P2 (A) and PI(3,4,5)P3 (B) and phosphatidic acid (PA) (C) of rested and stimulated 
(CRP, 10 µg/ml ; thrombin, 0.5 IU/ml) 32Pi-labelled platelets (mean ± SD; n=2). 
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Figure S5: Vps34 inactivation decreased thrombus growth. (A) Platelet adhesion on collagen surface 
after aIIbb3 integrin blockade. DiOC6-labelled platelets in whole blood treated with Integrilin
® (40 µg/ml) were 
perfused through a collagen-coated microcapillary at a physiological shear rate of 1500 s-1. Surface covered 
by fluorescent platelets was analyzed using ImageJ (mean ± SEM; n=3-5 mice of each phenotype). (B) 
Whole blood from WT mice was treated with VPS34-IN1 (1µM), SAR405 (1µM) or vehicle (DMSO) for 1 h. 
Then, DiOC6-labelled whole blood was perfused through a collagen-coated microcapillary at a physiological 
arterial shear rate of 500 s-1. Scale bar: 20 µm. Surface covered by fluorescent platelets and thrombus 
volume were analyzed using ImageJ (mean ± SEM; n=5 mice of each genotype; *p<0.05; **p<0.01 versus 
WT according to two-way ANOVA test and one sample t test).  
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Supplemental Figure 6 
Figure S6: Normal in vitro platelet aggregation when Vps34 is deleted or inactivated. (A) Washed platelet aggregation in response to 
collagen, CRP, thrombin or U46619 or in response to ADP was analyzed by light transmission aggregometry or by impedance aggregometry 
respectively. Representative curves are shown (n=6-15 mice of each genotype) (B) Washed platelets stimulated in suspension with CRP (1 µg/ml) 
were visualized by scanning electron microscopy. Two representative images of each genotype are representative of 5 mice. Scale bar: 1 µm. (C) 
Flow cytometry analysis of JON/A-PE antibody binding to platelets at resting or stimulated state. Results are cumulative data from 6 mice of each 
genotype and are presented as mean fluorescence intensity (MFI) ± SEM (*p<0.05 versus WT according to two-way ANOVA). (D) Reactive oxygen 
species (ROS) production in resting or stimulated (CRP, 1 µg/ml; thrombin, 0.1 IU/ml) platelets was analysed by flow cytometry using DCFH-DA 
compound (mean ± SEM; n=3 mice of each genotype). (E) TXA2 production in rested or stimulated (CRP, 1 µg/ml; thrombin, 0.1 IU/ml) platelets 
was analysed by mass spectrometry by quantifying its stable derivative TXB2 produced (mean ± SEM; n=3 mice of each genotype). (F) Platelet 
adhesion on collagen surface after COX blockade. DiOC6-labeled platelets in indomethacin (10µM) treated whole blood were perfused through a 
collagen-coated microcapillary at a physiological shear rate of 1500 s-1. Surface covered by fluorescent platelets and thrombus volume were 
analyzed using ImageJ (mean ± SEM; n=3 mice of each phenotype; *p<0.05; **p<0.01; ***p<0.001 versus WT according to two-way ANOVA test 
and one sample t test). (G) Platelet-rich plasma from human healthy donors was incubated with DMSO (vehicle) or 1 µM VPS34-IN1 during 1 h at 
37°C. Then, platelet aggregation in response to agonists was assessed by light transmission aggregometry. Aggregation curves are representative 
of 3 healthy donors. 
 
Video 1 : WT mice platelet rolling and adhesion on VWF surface. DiOC6-labelled platelets in WT mice whole 
blood was perfused through a VWF-coated microcapillary at a physiological shear rate of 1500 s-1. Transmitted 
light images were recorded at 0.2 image/sec over the perfusion period using Zen® Zeiss software. Scale bar : 
20 µm 
 
Video 2 : Pf4-Cre-Pik3c3lox/lox  mice platelet rolling and adhesion on VWF surface. DiOC6-labelled platelets in 
Pf4-Cre-Pik3c3lox/lox mice whole blood was perfused through a VWF-coated microcapillary at a physiological 
shear rate of 1500 s-1. Transmitted light images were recorded at 0.2 image/sec over the perfusion period using 
Zen® Zeiss software. Scale bar : 20 µm 
